PT  - JOURNAL ARTICLE
AU  - Al-Qahtani, Khalid H.
AU  - Al-Asiri, Mushabbab
AU  - Tunio, Mutahir A.
AU  - Aljohani, Naji J.
AU  - Bayoumi, Yasser
AU  - Al-Hussain, Hussain
AU  - Maklad, Ahmed M.
TI  - Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers
AID  - 10.15537/smj.2015.4.10341
DP  - 2015 Jan 01
TA  - Saudi Medical Journal
PG  - 442--448
VI  - 36
IP  - 4
4099  - http://smj.org.sa/content/36/4/442.short
4100  - http://smj.org.sa/content/36/4/442.full
SO  - Saudi Med J2015 Jan 01; 36
AB  - Objectives: To evaluate the clinicopathologic features, and explore the treatment outcomes of synchronous, or metachronous second primary malignancies (SPM) in conjunction with differentiated thyroid cancers (DTC).Methods: This retrospective study was conducted on 823 DTC patients treated between 2000 and 2012 at 2 tertiary care hospitals (King Fahad Medical City and King Khalid University Hospital) in Riyadh, Kingdom of Saudi Arabia. Forty-one (5%) DTC patients were found to have SPM (61% metachronous and 39% synchronous). These patients with SPM were studied for clinicopathological features and treatment outcomes.Results: The patients with DTC and SPM were older (median age: 54.3 years) than those without SPM (median age: 43.2 years); p=0.04. The frequency of SPM was breast (51.2%), colon (12.2%), kidney (7.3%), astrocytoma (7.3%), parotid (7.3%), rectum (4.9%), lymphoma (4.9%), nasopharynx (2.4%), and stomach (2.4%). Median follow-up was 8.05 years. Ten-year disease free survival, and overall survival (OS) rates were lower in DTC patients with SPM (56.1% for 10-year survival, and 71.7% for OS) than without SPM (95.5% for 10-year survival, and 97.8% for OS); p=0.0001. Metachronous SPM had better 10-year disease free survival rates (60.2%) than synchronous SPM (45%).Conclusion: The co-occurrence of SPM with DTC affects long-term disease free survival and OS rates.